Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Lilly reassures investors that weight-loss drug demand is strong, shares rise
Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
Zepbound sales keep soaring, even as weight loss drug growth slows
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s ...
NBC New York12d
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes ... to launch Mounjaro in new international markets throughout ...
NBC New York12d
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Retatrutide is a key part of Eli Lilly's drug pipeline that works ... appears to be even more effective at weight loss. "We believe this potential new medicine can deliver even more weight ...
NBC DFW12d
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Retatrutide is a key part of Eli Lilly's drug pipeline that works ... "We believe this potential new medicine can deliver even more weight loss than tirzepatide and it could potentially provide ...